E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer
Type
ArticleAuthors
Kothandaraman, NarasimhanBajic, Vladimir B.

Brendan, Pang NK
Huak, Chan Y
Keow, Peh B
Razvi, Khalil
Salto-Tellez, Manuel
Choolani, Mahesh
KAUST Department
Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) DivisionComputational Bioscience Research Center (CBRC)
Applied Mathematics and Computational Science Program
Date
2010-02-24Online Publication Date
2010-02-24Print Publication Date
2010-12Permanent link to this record
http://hdl.handle.net/10754/325253
Metadata
Show full item recordAbstract
Background: Ovarian epithelial cancer (OEC) usually presents in the later stages of the disease. Factors, especially those associated with cell-cycle genes, affecting the genesis and tumour progression for ovarian cancer are largely unknown. We hypothesized that over-expressed transcription factors (TFs), as well as those that are driving the expression of the OEC over-expressed genes, could be the key for OEC genesis and potentially useful tissue and serum markers for malignancy associated with OEC.Methods: Using a combination of computational (selection of candidate TF markers and malignancy prediction) and experimental approaches (tissue microarray and western blotting on patient samples) we identified and evaluated E2F5 transcription factor involved in cell proliferation, as a promising candidate regulatory target in early stage disease. Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.Results: Analysis of clinical cases shows that of the E2F5 status is characteristic for a different population group than one covered by CA125, a conventional OEC biomarker. E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used). This significantly improved accuracy suggests possibility of an improved diagnostics of OEC. Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.Conclusions: Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis. 2010 Kothandaraman et al; licensee BioMed Central Ltd.Citation
Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, et al. (2010) E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer 10: 64. doi:10.1186/1471-2407-10-64.Publisher
Springer NatureJournal
BMC CancerPubMed ID
20181230PubMed Central ID
PMC2841139ae974a485f413a2113503eed53cd6c53
10.1186/1471-2407-10-64
Scopus Count
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Related articles
- B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
- Authors: Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW
- Issue date: 2006 Feb 1
- Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.
- Authors: White NM, Mathews M, Yousef GM, Prizada A, Fontaine D, Ghatage P, Popadiuk C, Dawson L, Doré JJ
- Issue date: 2009
- [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
- Authors: Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H
- Issue date: 2008 Dec
- Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
- Authors: Chauhan SC, Vinayek N, Maher DM, Bell MC, Dunham KA, Koch MD, Lio Y, Jaggi M
- Issue date: 2007 Aug
- The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
- Authors: Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr
- Issue date: 2008 Feb